[HTML][HTML] Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
S Shyam Sunder, UC Sharma… - Signal Transduction and …, 2023 - nature.com
Since their invention in the early 2000s, tyrosine kinase inhibitors (TKIs) have gained
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …
prominence as the most effective pathway-directed anti-cancer agents. TKIs have shown …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after …
JPH Machiels, RI Haddad, J Fayette, LF Licitra… - The Lancet …, 2015 - thelancet.com
Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and
neck (HNSCC) progressing after first-line platinum regimens have a poor prognosis and few …
neck (HNSCC) progressing after first-line platinum regimens have a poor prognosis and few …
[HTML][HTML] A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck
TY Seiwert, J Fayette, D Cupissol, JM Del Campo… - Annals of oncology, 2014 - Elsevier
Background Afatinib is an oral, irreversible ErbB family blocker that has shown activity in
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
epidermal growth factor receptor (EGFR)-mutated lung cancer. We hypothesized that the …
[HTML][HTML] Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK
R Califano, N Tariq, S Compton, DA Fitzgerald… - Drugs, 2015 - Springer
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib,
erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced …
erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced …
Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer
T Nagano, M Tachihara… - Current cancer drug …, 2019 - ingentaconnect.com
Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …
Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?
SJC Van der Stegen, DM Davies, S Wilkie… - The Journal of …, 2013 - journals.aai.org
The ErbB network is dysregulated in many solid tumors. To exploit this, we have developed
a chimeric Ag receptor (CAR) named T1E28z that targets several pathogenetically relevant …
a chimeric Ag receptor (CAR) named T1E28z that targets several pathogenetically relevant …
Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors
V Hirsh, N Blais, R Burkes, S Verma, K Croitoru - Current oncology, 2014 - mdpi.com
Abstract Treatment for non-small-cell lung cancer (nsclc) is moving away from traditional
chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) …
chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) …
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review
J Köhler, M Schuler - Onkologie, 2013 - karger.com
Non-small cell lung cancer (NSCLC) consists of several histomorphologically defined
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …
phenotypes that display an enormous genetic variability. In recent years, epidermal growth …